Purpose Clinical trial study failures cause significant disruptions to supply chain operations, which lead to operational inefficiencies and financial losses. Methods In this paper, a framework to construct a Bayesian belief network (BBN) by leveraging subject matter expertise and probabilistic elicitation methods to quantify the probability of a disruption to a clinical supply chain is presented. Results The effect of varying input factors on a disruption probability is studied, and new metrics are developed to evaluate the significance of a disruption. Conclusions This framework allows practitioners to assess the probability of disruptions to their network, thus enabling targeted strategies to be developed and implemented.
Introduction
The outcomes of clinical trial studies are closely tied to ongoing drug development, which may lead to changes in drug design and other experimental parameters. As a result, firms are faced with major issues ranging from maintaining market share for a given therapeutic area to mitigating supply issues related to the sourcing raw materials. These challenges cause cascading supply chain disruptions, which may lead to delays in conducting trials and successfully getting a drug to market. Thus, there is a need for full visibility into these supply-related and industryrelated factors, in order to develop an appropriate strategy ensuring the timely delivery of clinical supplies. More specifically, the ability to model the relationships between these factors can help firms prioritize critical factors, across all stages of development, where resources should be allocated to manage uncertainty. This research proposes using Bayesian belief networks (BBNs) to model and analyze the complex relationships within a clinical supply chain. In particular, this method is used to quantify the probability of a disruption at different stages in the clinical supply chain, and determine where purchasing and supply risk management efforts should be allocated to reduce the probability of a disruption.
Clinical trials are a phased series of experiments, required by the Food and Drug Administration (FDA), to produce new drugs and medical devices in the USA [41] . To obtain FDA approval to market and sell their products, firms must demonstrate human safety and efficacy in their clinical studies. Clinical trials are classified into five phases shown in Table 1 . Each phase has a probability that the drug passes the trial, and the overall likelihood of a drug successfully reaching approval is approximately 10% [17, 37] . Phase II is the most challenging phase of clinical trials, with approximately 31% of drugs successfully transitioning to phase III [17] .
Upon a failed study, the FDA may allow firms to modify their drug formulation and conduct additional trials to assess safety and efficacy. These frequent study failures (which occur at a rate of approximately 90%) and formulation changes lead to a constant state of disruption in clinical supply chains. For instance, a formulation change requires modifications to manufacturing processes, which may impact capacity planning, purchasing requirements, purchasing and supply strategies for raw and in-process materials, and resource management. Furthermore, frequent changes in production processes detract from employee productivity, as employees are unable to develop process familiarity. Conversely, a firm may decide that it is no longer financially viable to invest in an experimental drug [11] . Thus, firms may be left with excess inventory with no salvage value.
The aforementioned challenges associated with clinical supply chains lie at the nexus of three distinct areas of the literature-(1) supply management, (2) supply chain disruption management, and (3) supply chain planning under uncertainty. Each of these areas are well-studied, with recent literature focusing on providing guidance on how to mitigate and understand some of these challenges on a macro scale.
Specific to the domain of supply management, recent research has focused on developing analytical methods and strategic pathways that enable better visibility and coordination throughout the network in order to mitigate uncertainty. For instance, related to the problem domain, Peterson et al. [50] developed a simulation approach that models automated dispensing and inventory management of clinical supplies, which led to significant savings due to reduced waste. Also, on clinical supply chains, Fleischhacker et al. [14] developed multi-echelon inventory models, formulating the problem as a nonlinear integer program, to address these aforementioned challenges. On a more macro level, Yeo and Yuan [64] extended the periodic review model to consider supply uncertainty and demand cancelation, with the goal of minimizing the variance of the supply yield or demand cancelation. Similar work considering supply uncertainty was done by Cheong and White [8] for discrete state systems, and by Kaki et al. [22] for the newsvendor problem.
In addition to using supply management practices to understand and manage uncertainty and supply and demand, better collaboration between processes, suppliers, and customers throughout the network are critical to supply chain performance. Lockstrom et al. [31] , for example, investigated key factors that influence supplier integration in the automotive industry. Specifically, they found that buyer-side leadership is a critical precursor to successful integration. Li et al. [29] developed a coordination model between subcontractors and integrated service suppliers which enhanced capacity coordination, thus mitigating uncertainty. Xu et al. [63] formulate and solve a stochastic optimization model to determine the optimal buyer flexibility strategies considering supply uncertainty under various scenarios where the primary supplier controls the wholesale price. Additional methods include game theoretic models [13] , optimal scheduling of upstream and downstream processes and suppliers [44] , and network design models [54] .
In the context of supply chain disruption management, researchers have deployed sophisticated, data-driven methods with roots in advanced statistics, operations research, and simulation to assess and mitigate the risks associated with disruptions on supply chain networks throughout the network. From recent literature, widely held methods include the analytic hierarchy process (AHP) [56] , real options theory [10] , petri nets [67] , portfolio optimization [55] , clustering analysis [3] , and various stochastic optimization methods that leverage simulation tools [33] , fuzzy inference tools [48] , and twostage modeling approaches [58] . Table 1 Clinical trial phases, scope and objectives [41] , and probability and cumulative probability of success [17] Lastly, recent literature in the area of supply chain planning under uncertainty has leveraged similar analytical methods used to study supply chain disruptions to inform operational planning decisions, while considering uncertainty. Similar to the models used to study supply chain risks and disruption, many of these analytical methods rely heavily on operations research methods with inherent stochasticity. Specifically, fuzzy methods [20, 36, 45, 49] , multiple objectives [35] , and decomposition methods [65, 66] have been used under these circumstances. Analytical models specific to the pharmaceutical industry have also been developed to determine optimal supply planning decisions in order to safeguard against shortages [1] .
The aforementioned methods in the literature may help to mitigate a portion of the supply management challenges faced by clinical supply chains. Unfortunately, however, since these networks are under a constant state of disruption due to multiple external factors with limited process knowledge and data, there is a need for an end-to-end planning tool that enables clinical supply chain practitioners to develop and implement strategies to improve supply chain performance.
Thus, in this paper, an analytical framework is presented that leverages causal networks, subject matter expertise, probabilistic elicitation, and empirical data to construct BBNs that allows practitioners to quantify the likelihood of a disruption, enabling organizations to develop targeted supply risk mitigation strategies. A full model for the supply chain and possible disruption factors was constructed using input from subject matter experts. Additionally, new metrics are proposed to quantify the impact of the disruption on a supply chain, and a simulation method to test different scenarios and the corresponding disruptions is employed. This method also allows for sensitivity analysis to determine which nodes cause the highest probability of disruption, and estimate the effect of incorrect parameter estimation. The flexibility of this method allows for uncertainty quantification of numerous scenarios and helps the analyst understand the risk and implications of managerial decisions. The BBackground^section of this paper discusses clinical supply chain processes and challenges and provides an overview of BBNs employed as risk analysis tools. The BModel Development^section details the analytical framework of constructing the BBN and the proposed metrics for evaluating the impact of a disruption. Finally, the BExperimental Results^section demonstrates the method with numerical examples that demonstrate how the model can be used to test a variety of scenarios. In particular, the sensitivity of the probability of disruption to various procurement issues, a changing study design or drug formulation, and a natural disaster on the supply chain are investigated and studied with the model. The BConclusions^section concludes.
Background
This section discusses the background and literature related to three main areas: clinical supply chain operations, clinical trials, and Bayesian belief networks. The goal is to provide a framework for understanding the model which will be presented in the BModel Development^section.
Clinical Supply Chain Operations Figure 1 displays an illustration of typical process steps in a clinical supply chain in the form of a causal network. Causal networks are graphical representations of a sequential event in the form of a directed acyclic graph comprised of a series of nodes and arcs [9] . In this illustration, the nodes represent clinical supply chain process steps, and the arcs depict a sequential (or causal) relationship between two nodes. Additionally, in this illustration, each node (or process) can exist in either one of two states-BNormal Operations^or BDisrupted Operations.^If a process is operating according to business as usual, then it falls under the BNormal Operations^category. Otherwise, upon experiencing any sort of disruption or complication, the process is placed in the BDisrupted Operations^category. Ultimately, firms aim to reduce the likelihood of a process existing in a disrupted state via various mitigation strategies.
Upon identifying the key clinical trial needs in the supply planning process (such as study complexity, the scope of work, key deliverables, study timelines and milestones, the type of study, trial phase, dosage form, and the country of the study location [19] ), firms can begin to procure the appropriate raw materials to initiate the production process. These raw materials are used throughout the production process from drug substance production through finished goods packaging. Production begins with the manufacture of the drug substance, which is the active pharmaceutical ingredient (API) in a drug product (DP) intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans or other animals. Drug products are the finished dosage form containing the drug substance (e.g. tablets, capsules, injectable, etc.) [52] . Primary packaging materials are those in direct contact with the drug product (e.g., blister packaging, bottles, vials, etc.). Finished goods packaging is where secondary packaging materials (e.g., patient kits, boxes, wallets, etc.) are assembled for delivery to the site of the clinical study [62] .
Success and Risk Factors of Clinical Trials
This failure rate (or success rate) of drugs in clinical trials depends on a multitude of factors-many of which are highly stochastic and uncontrollable for firms. Clinical approval rates differ by therapeutic area, which is partially explained by the differing scientific objectives and underlying science knowledge base for a given drug class [12] . Success rates across all therapeutic areas and phases of study range from 5.1 to 26.1% [17] . Additionally, depending on the location of the clinical studies, firms may have limited expertise in handling regulatory requirements in different countries. This may lead to multiple layers of review and increased regulatory scrutiny [42] . Furthermore, the advantages of being the first product to the market for a particular indication create competition between companies. On average, first entrants achieve a minimum of 7% more market share over their competitors [6] . As a result, the loss of potential market share from not being first-tomarket may drive a firm to abandon research efforts.
From a quality management perspective, ensuring product quality throughout the clinical supply chain can be particularly challenging. In such a disruptive environment, it is often quite difficult to ensure timelines are satisfied, especially when resources are constrained. Because of this, firms may rely on contract research organizations or contract development and manufacturing organizations to scale up research efforts and manage the clinical supply chain. If communication, project management, and risk mitigation efforts between the firm and these entities fall short, product quality may suffer, which may lead to poor trial outcomes [57] .
Additionally, the clinical trial enrollment and study design are particularly important to the success of clinical trials [16] . For instance, enrollment in clinical trials for oncology patients is relatively low, with approximately 2 to 3% of all oncology patients enrolling in clinical trials [38] . Under these circumstances, when the clinical study design includes a treatment arm that may be perceived to be more aggressive or favorable than the alternative, this may further reduce enrollment, and potentially put the study at risk of failure [32] .
With companies spending an average of approximately $33.4M throughout the clinical trial process, developing an understanding of the key factors associated with clinical trial success is of elevated importance to supply chain organizations [34] . More specifically, the uncertainty associated with clinical trial outcomes, which may create cascading disruptions throughout a clinical supply chain, is of particular importance to the purchasing and supply functions. The inability to meet quantity demand, discontinuity of supply, geographic concentrations of suppliers, among other supply risks are particularly relevant in supply chain networks with similar characteristics [68] .
The ability to readily identify key risk factors in a clinical supply chain, allows for a better understanding of network performance and potential areas of vulnerability [60] . Understanding the relationships between these influencing factors enables individual companies to develop targeted strategies to improve performance, minimize cost and risk, and reap the benefits of being the first-to-market [7] .
Bayesian Belief Networks
A BBN is a probabilistic model graphically depicted in the form of a directed acyclic graph containing a set of interconnected nodes [25] . Each node of a BBN represents a discrete or continuous random variable X i . The connecting arcs represent conditional dependencies between random variables, with the direction indicating a causal relationship [53] .
For example, the BBN in Fig. 2 describes the manufacturing and inventory decisions based on a drug product's therapeutic area, formulation, and the size of the clinical study for which the drug product is required. Each of these events is represented as discrete categorical variables with two states. Given the parent node probabilities and conditional probabilities associated with the children nodes, as shown in the conditional probability tables (CPTs) next to each node in the network, the probability of a given series of events can be calculated as follows:
where P(X i = x i | Parents(X i )) is the probability that the node for random variable X i is in state x i given the states of the parent nodes of X i . As defined in Eq. 1, for a collection of n events, each of which denoted by X i , the probability of a series of events is calculated based on the conditional probabilities within the network. For example, the probability that a metabolic disease, solid dosage drug product for a small clinical trial (less than 300 patients) is manufactured in-house with increased inventory levels is calculated as:
Probabilistic Elicitation to Model Uncertainty
In the event that there is insufficient or unreliable data to populate the CPT, BBNs can accommodate subjective or objective estimates of probabilities. Under these circumstances, researchers employ elicitation methods to translate expert judgments into probabilities and/or probabilistic distributions, which can then be used to approximate conditional probabilities, quantify risks, and predict the frequency of future events [39] . Probabilistic elicitation is an iterative process of collaborating with subject matter experts (SMEs). First, SMEs must identify which events require elicitation. Next, upon eliciting probabilities from SMEs, a probability distribution is derived. Finally, if possible, researchers then assess the adequacy of the results and, if necessary, return to the SMEs to elicit further information.
Throughout this process, consensus among the SMEs is critical. To accommodate this, Witteman and Renooij [61] developed a response scale, as depicted in Fig. 3 , which translates verbal responses to probabilistic values.
Applying this elicitation scale to the example shown in Fig.  2 allows the uncertainties in the conditional probability table values to be represented as ranges to be incorporated into the BBN model. This representation is shown in Fig. 4 .
Under this context, the probability that a solid dosage drug product for a small clinical trial (less than 300 patients) for a metabolic disease is manufactured in-house with increased inventory levels can be approximated. Table 2 provides a summary of key features of recent related research, with emphasis on supply chains, manufacturing, and healthcare applications.
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In the context of supply chain operations, Pai et al. [46] were among the earliest researchers to apply BBNs to model risk and uncertainty in supply chains by incorporating supply chain risk measures associated with increasing complexity of supply networks and resulting cascading effects of disruptions. Kaki et al. [23] discuss the analysis of supply chain disruptions to mitigate risk, applying probabilistic risk assessment and simulation in combination with expert interviews. Garvey et al. [15] construct a network-based BBN model to evaluate supply chain disruptions resulting from network risk propagation. Hosseini and Barker [18] build a BBN for the supplier selection problem based on resilience factors. The authors perform a sensitivity analysis to show the impact of varying different probabilities in the network on its resilience. A propagation analysis is also performed to see the effect of different scenarios being realized on the different suppliers. Qazi et al. [51] extend the work of Garvey et al. [15] to integrate the stages of the risk management process and determine the prioritization of risk mitigation strategies. The authors focus on different risk measures to quantify the loss associated with supply chain risk where there is a budget that can be allocated to mitigating risk at various parts of the network.
In manufacturing applications, Buyukozkan et al. [5] study the impact of lean manufacturing on financial, non-financial, and sustainability performance, using BBNs to define the inter-and intra-relationship of lean factors, including the effects of combinations of lean factors under changing conditions. Bouaziz et al. [4] assess risk the of equipment failure and production machine drift in semiconductor manufacturing environment by leveraging a combination of operational data and subject matter expertise. Similarly, Li et al. [28] use a fault diagnosis expert system to diagnose possible root causes of BBNs have also been leveraged as an analytical tool for healthcare applications. For instance, Papaconstantinou et al. [47] apply a BBN model to determine patient eligibility for clinical trials. Liu et al. [30] apply BBNs to study the health risks of non-carcinogenic substances by combining epidemiological study data and hospital attendance records to establish a probabilistic relationship between air pollutants and the resulting health consequences. Steele et al. [59] address the problem of Clostridium difficile (C-Diff) infection following colorectal resection by using machine-learned BBNs to preoperatively provide clinicians with postoperative estimates of C-diff risk. Using the Nationwide Inpatient Sample national registry dataset, the models were able to produce robust estimates of postoperative infection, allowing clinicians to identify highrisk patients and potentially implement measures to reduce the incidence and morbidity of C-Diff. Kazemi et al. [24] describe the use of BBNs and probabilistic elicitation methods to examine patient-level factors and physicianlevel decisions and factors which contribute to the risk of hospital-acquired adverse events and support hospital decisions on staffing, length of stay, and investments in safety. The models they develop have both a qualitative and quantitative aspect; experts' assessment on parameters for which no data or unreliable data was available was elicited through multiple face-to-face interviews, and combined with available field data.
Outside of the aforementioned problem domain areas, BBNs have been widely studied across multiple problem domains, such as transportation services [2] , forest management Nyberg et al. [43] , and natural disasters [21, 27] . Additionally, Lauria and Duchessi [26] provide guidance on building BBNs from existing data.
In this research, the primary contribution is the development of a framework to assess the impact of disruptions on clinical supply chain performance. This enables firms to identify key factors and variables within the network that heavily influence clinical supply chain performance. Armed with this information, firms can rank and prioritize these factors for long-term operational planning purposes. More specifically, with this knowledge, clinical supply chain practitioners are better able to develop targeted mitigation strategies to minimize the frequency and impact of network disruptions.
Model Development
Throughout this process, using elicitation methods, subject matter experts in the pharmaceutical industry share their 
knowledge about the problem domain. As previously stated, the goals of this exercise are to quantify the impact of a disruption to a clinical supply chain in the absence of data, and to determine points in the network that are particularly vulnerable upon experiencing a disruption. The first step in this process is to identify the supply chain network configuration, similar to the causal network shown earlier in Fig. 1 . This is executed by identifying the flow of raw materials, drug substance, drug product, and finished goods through the supply chain to delivery at the site. Each operation (or process) within the clinical supply chain is considered to be a node in a causal network, which has two states: a desirable state, which is the state at which the node is fully operational, and an undesirable state, which is the state at which the node experiences a disruption.
Next, as shown in Fig. 5 , a brainstorming exercise with the subject matter experts is completed to identify potential disruption sources. Each disruption source is considered as a binary state node, similar to the nodes of the supply chain network. The SMEs then cluster the nodes and create distinct categories based on their similarities. With the nodes generated from these exercises, the SMEs create a causal network, linking the disruption sources to the clinical supply chain network. Each child node is limited to at most 2 parent nodes. Given that each of the nodes has binary states, this causal network is the foundation of the BBN. Using the elicitation scale in Fig. 3 , the SMEs populate the associated CPTs for the BBN.
To assess the impact of a disruption on the network using Table 3 as a guide while collaborating with the SMEs, a disruption impact score, d i is assigned for each of the n nodes in the network. For each node in the network, a nodal disruption score, DS i is computed, where DS i = p i d i . The value of p i is the probability that node i is in an undesirable state and is estimated computationally using BBN logic. Using the overall disruption score, noted as DS overall , the vulnerability of the network is assessed by computing the sum of the nodal disruption scores, which is given by DS overall ¼ ∑ n i¼1 DS i .
Finally, the Bbnlearn^package in R [40] is used to construct and exercise the model. This package constructs the BBN and calibrates the conditional probability tables either using data or by entering the tables with values chosen by the model experts. Then, by entering the conditional probabilities as variables, a sensitivity analysis is conducted to determine the model's robustness to changes in these values.
The package allows realizations of the network to be simulated in order to estimate the probability of disruption p i . For each set of simulated realizations, the nodal disruption scores are calculated for each of the supply chain nodes that are simulated to be in an undesirable state. This yields an overall disruption score for a set of model inputs.
Experimental Results
A BBN is constructed for a clinical pharmaceutical supply chain with the factors that influence it. Applying the methodology in the BModel Development^section, the SMEs created the causal network shown in Fig. 6 with the nodes and states defined in Table 4 , and the parents, children, and disruption scores outlined in Table 5 . The supply chain network consists of 13 nodes (in red in Fig. 6 ), while the SMEs identified 16 disruption sources on the network.
The 13 supply chain nodes describe how raw materials, drug substance, drug products, and finished goods move through the network from demand planning, production, and delivery to the clinical site. As identified by the subject matter experts, the 16 disruption sources are linked to the supply chain network to show the relationship between these factors and supply chain operations. Additionally, the disruption sources may also be interrelated, and are grouped into 7 distinct categories based on similarities, as shown in Table 4 . Using this causal network, the SMEs use the elicitation scale to populate the CPTs in order to build the BBN. Furthermore, elicited disruption impact score values for the supply chain network nodes are given in Table 3 .
The network, as specified by the SMEs, is constructed in R so that the probability of a node disruption can be calculated for different possible values in the CPTs. In the baseline case, all node CPT values are set by the SMEs, and the probability of disruption at each node is evaluated. This is used to calculate an overall disruption score of 188.6. While this value is not meaningful on its own, it can be used as a relative metric to compare against different scenarios to determine which situations have a higher overall disruption impact. This framework can be used to study the impact on the disruption score based on the acquisition of additional information about the system. For example, if evidence suggests that a particular supply chain or input factor node is in a particular state, this model can approximate the resulting impact to the network. The sensitivity of the model to changes in SME input is also of interest and must be investigated. Since the CPTs are estimated often using qualitative knowledge of the system, testing the effect of changes in CPT values can help predict the effect of model error. In addition to the baseline scenario, four distinct scenarios are tested, as shown in Table 6 and assess the effect on the overall disruption score in the next sections.
Case 1 Simulation Results: Randomizing the Probability of a Disruption in Procurement
In case 1, the impact of competitors posing procurement challenges when purchasing drug product for head-to-head clinical studies is analyzed. To study this, the probabilities of three input nodes in the network being in undesirable states are randomized: V2 (sourcing challenges), G3 (enrollment pace vs. plan), and S1 (competitive landscape changes priority). Since the values in the conditional probability tables are estimated by subject matter experts, this exercise enables further understanding of the sensitivity of the overall network to these input values. Figure 7 compares the network disruption scores for each of the simulation trials for case 1 to the baseline case (case 0). As displayed in Fig. 7 , the solid flat line represents the baseline scenario, which has a disruption score of 188.6. The probabilities associated with the three nodes V2, G3, and S1 are varied separately to see the effect on the overall network. As expected, for all three input nodes individually, as the probability of disruption increases, the overall network disruption scores increase accordingly.
The overall network disruption score appears to be least sensitive to node S1 (competitive landscape changes priority), with the score only increasing slightly as this probability of disruption increases. This implies that an increase in priority driven by competitors in the same therapeutic area is essentially business as usual. Oppositely, however, the model appears most sensitive to G3 (enrollment pace vs. plan), implying that slow enrollment in clinical trials poses significant risks to the clinical supply chain network. Sourcing challenges (node V2) also increase the overall disruption score as the probability of a disruption at that node increases. 
Cases 2 Through 4: Investigating Vulnerabilities upon Experiencing Disruptions
In cases 2 through 4, supply chain network disruptions are further investigated by studying specific disruption scenarios. Specifically, in case 2, a scenario with an adaptive study design is used and causes study design changes. This implies that there is evidence suggesting that input nodes SD3 (adaptive design) and SD4 (study design changes) both have disruptions and exist in the Bpresent^state. In case 3, a scenario is recreated where poor study results drive a formulation change, implying that evidence suggests that node SD1 (changes in drug product) has a disruption existing in the Bpresent^state, and node D1 (study results) exists in the Bnegative^state. Lastly, in case 4, a scenario in which a natural disaster causes network outages and a loss of clinical supplies is investigated, implying that evidence suggests that node DR1 (political/natural disaster frequency) is present in the Bhigh^disruption state, and node V2 (sourcing challenges) disruption exists in the Bpresent^state. For each of these cases, areas of vulnerability relative to the baseline are analyzed.
In cases 2 through 4, the overall network disruption scores are 188.9, 195.9, and 213.0, respectively. With the baseline score having an overall network disruption score of 188.6, this implies that cases 2 and 3 are reasonable scenarios, which a typical clinical supply chain network can handle. However, case 4 has an elevated network disruption score relative to the baseline, which may have the potential to put the network at risk.
These findings are further highlighted by the analysis presented in Fig. 8 . Upon analyzing the mean disruption probabilities relative to the baseline, in case 2, the network is not significantly impacted upon experiencing this particular form of disruption. Furthermore, the probability of disruption for each individual supply chain node is within 3% of the baseline case, with the highest increase in disruption at SCM1 (raw material procurement operations) and SCM2 (raw material inventory operations) and the largest decrease in disruption at SCM4 (drug product manufacturing) and SCM5 (finished goods). Competitors make it different to procure their product for head-to-head studies.
Randomize V2, G3, and S1 probabilities Case 2
Using an adaptive study design inherently causes study design changes.
P(SD3 = Present) = 1P(SD4 = Present) = 1
Case 3
Poor study results cause leadership to change the formulation of a drug product from a capsule to a coated tablet for clinical studies. Similar results were found for case 3; however, SCM9 (drug product inventory) saw an increase of 14% from the baseline. Per the structure of the BBN network, SD1 is a parent node for SCM9. Furthermore, upon closely observing the network, SCM9 is centrally located within the network with many nodes preceding it upstream and following downstream in the BBN structure.
Case 4 has a more dramatic impact on the clinical supply chain network. With an overall network disruption score of 213, which is much higher than the baseline and cases 2 and 3, the supply chain network is particularly vulnerable with node SCM1 (raw material procurement operations) seeing a 220% increase, SCM2 (raw material inventory operations) with a 154% increase, SCM3 (drug substance manufacturing) with a 30% increase and SCM11 (shipment to Site) with a 71% increase. Given the locations of the input nodes under investigation for this case, DR1 and V2, the findings for case 4 are partially related to the network structure.
Discussion
As shown in the numerical results presented in this section, it has been demonstrated that leveraging Bayesian belief networks to assess disruptions in a clinical supply chain can help practitioners better understand network behavior and vulnerabilities in the absence of data. This is a critical contribution, since the problems and challenges faced by clinical supply chain practitioners often occur quite frequently, thus causing cascading network disruptions. Given these properties, the framework presented in this paper enables firms to develop strategic mitigation Fig. 8 Supply chain network vulnerability efforts that are targeted at vulnerable areas of the network, based on input from subject matter experts.
Additionally, the numerical exercises presented in this section imply that many of the disruptions experienced in a clinical supply chain network are closely related to business-asusual operations. While further research is required to investigate this finding, this suggests that there is a reasonable level of disruption that is to be expected within the network. Thus, under these circumstances, the proposed mitigation strategies must enable clinical supply chain operations to manage these variations efficiently under business-as-usual circumstances, while safeguarding a firm against high impact disruptions in order to maintain performance.
Ultimately, from a purchasing and supply management perspective, the framework presented in this paper is an important precursor to assessing risk throughout the network. With this holistic, end-to-end view of clinical supply operations, leadership can create targeted supply strategies to reduce uncertainty and supply risks. This, in addition to the traditional, datadriven analytical methods to assess supply risk and manage supply chain operations, can lead to the development of sustainable purchasing and supply management practices that facilitate a competitive advantage in clinical trials.
Conclusions
In this research, an analytical framework to assess the likelihood and impact of disruptions on a clinical supply chain network is presented. Specifically, a Bayesian belief network is constructed with the input of subject matter experts, using probabilistic elicitation methods, and thus used as a tool to investigate and evaluate various disruption scenarios. These research contributions enable clinical supply chain practitioners to identify key factors and variables within the network that heavily influence clinical supply chain performance. With this knowledge, industry leaders can readily identify and prioritize areas of vulnerability within the supply chain network. Furthermore, with this knowledge, clinical supply chain practitioners are able to implement targeted strategies to mitigate the impact of network disruptions and supply risks.
With that said, however, this research should be extended to further investigate ways to enhance model capabilities. Based on this research, an important extension would be a study on input uncertainty and the resulting impact on output variability. Since the BBN model relies on elicited probabilities from subject matter experts, in addition to the inherent stochasticity of the problem under investigation, there is an additional level of uncertainty associated with the elicited probability values. A rigorous statistical study is required to fully assess the impact of the stochastic input values on the model output beyond the simulation studies conducted in this research.
A second potential extension of this research would be to study the effects of various purchasing and supply management strategies using the BBN model. Using the business-asusual case as a starting place, firms can collaborate with subject matter experts to include targeted strategies in the BBN model in the form of nodes in the network. Then, following the procedures outlined in the BModel Development^section of this paper, firms can then study the impact of the individual strategies on network performance. This may be further extended by formulating and solving a constrained optimization model to determine the optimal combination of purchasing and supply management strategies that maximizes performance or minimizes risk.
In a nutshell, the framework presented in this research can be applied to solve problems where data collection efforts are too resource intensive or impossible to execute due to a lack of process maturity. Collaborating with subject matter experts to build analytical models based on elicited probabilities can serve as a surrogate for solving problems in complex networks with limited information.
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